OBJECTIVE: Vascular cell adhesion molecule-1 (VCAM-1), an adhesion molecule, is involved in the progression of glomerular and tubulointerstitial injury. Neutrophil gelatinase-associated lipocalin (NGAL), a member of the lipocalin superfamily, has been shown to rise in both acute and chronic kidney damage. Both VCAM-1 and NGAL have been found at high levels in the urine of patients with active lupus nephritis. We investigated both as potential biomarkers for lupus nephritis. METHODS: VCAM-1 and NGAL were measured by ELISA during 1 to 8 clinic visits in 107 patients with systemic lupus erythematosus (SLE; 91% women, 51% black, 36% white, 4% Asian, 4% Hispanic, and 5% others) for a total of 190 visits. Patients' mean age was 41 years. We analyzed the relationship between these potential urine biomarkers and the urine protein/creatinine ratio (urine Pr/Cr), the Systemic Lupus International Collaborating Clinics (SLICC) renal activity score, SLE Disease Activity Index renal descriptors, and other clinical variables. RESULTS: VCAM-1 levels were strongly associated with the physician's global estimate of disease activity (p = 0.0002), the renal visual analog scale (p < 0.0001), the urine Pr/Cr (p < 0.0001), and SLICC renal activity score (p < 0.0001). VCAM-1 levels were also associated with a urine Pr/Cr ≥ 0.5 (p < 0.0001). NGAL was not associated with any measure of disease activity or with lupus serologies. CONCLUSION: Urine VCAM-1 had a strong association with measures of disease activity, including multiple renal activity descriptors. In contrast to previous SLE studies, NGAL failed to show any association with lupus nephritis.
OBJECTIVE:Vascular cell adhesion molecule-1 (VCAM-1), an adhesion molecule, is involved in the progression of glomerular and tubulointerstitial injury. Neutrophil gelatinase-associated lipocalin (NGAL), a member of the lipocalin superfamily, has been shown to rise in both acute and chronic kidney damage. Both VCAM-1 and NGAL have been found at high levels in the urine of patients with active lupus nephritis. We investigated both as potential biomarkers for lupus nephritis. METHODS:VCAM-1 and NGAL were measured by ELISA during 1 to 8 clinic visits in 107 patients with systemic lupus erythematosus (SLE; 91% women, 51% black, 36% white, 4% Asian, 4% Hispanic, and 5% others) for a total of 190 visits. Patients' mean age was 41 years. We analyzed the relationship between these potential urine biomarkers and the urine protein/creatinine ratio (urine Pr/Cr), the Systemic Lupus International Collaborating Clinics (SLICC) renal activity score, SLE Disease Activity Index renal descriptors, and other clinical variables. RESULTS:VCAM-1 levels were strongly associated with the physician's global estimate of disease activity (p = 0.0002), the renal visual analog scale (p < 0.0001), the urine Pr/Cr (p < 0.0001), and SLICC renal activity score (p < 0.0001). VCAM-1 levels were also associated with a urine Pr/Cr ≥ 0.5 (p < 0.0001). NGAL was not associated with any measure of disease activity or with lupus serologies. CONCLUSION: Urine VCAM-1 had a strong association with measures of disease activity, including multiple renal activity descriptors. In contrast to previous SLE studies, NGAL failed to show any association with lupus nephritis.
Authors: M H Biezeveld; G van Mierlo; R Lutter; I M Kuipers; T Dekker; C E Hack; J W Newburger; T W Kuijpers Journal: Clin Exp Immunol Date: 2005-07 Impact factor: 4.330
Authors: G Contreras; V Pardo; C Cely; E Borja; A Hurtado; C De La Cuesta; K Iqbal; O Lenz; A Asif; N Nahar; B Leclerq; C Leon; I Schulman; F Ramirez-Seijas; A Paredes; A Cepero; T Khan; F Pachon; E Tozman; G Barreto; D Hoffman; M Almeida Suarez; J C Busse; M Esquenazi; A Esquenazi; L Garcia Mayol; H Garcia Estrada Journal: Lupus Date: 2005 Impact factor: 2.911
Authors: Michelle Petri; Mimi Y Kim; Kenneth C Kalunian; Jennifer Grossman; Bevra H Hahn; Lisa R Sammaritano; Michael Lockshin; Joan T Merrill; H Michael Belmont; Anca D Askanase; W Joseph McCune; Michelene Hearth-Holmes; Mary Anne Dooley; Joan Von Feldt; Alan Friedman; Mark Tan; John Davis; Mary Cronin; Betty Diamond; Meggan Mackay; Lisa Sigler; Michael Fillius; Ann Rupel; Frederick Licciardi; Jill P Buyon Journal: N Engl J Med Date: 2005-12-15 Impact factor: 91.245
Authors: G Moroni; S Pasquali; S Quaglini; G Banfi; S Casanova; M Maccario; P Zucchelli; C Ponticelli Journal: Am J Kidney Dis Date: 1999-09 Impact factor: 8.860
Authors: Andrea Fava; Jill Buyon; Chandra Mohan; Ting Zhang; H Michael Belmont; Peter Izmirly; Robert Clancy; Jose Monroy Trujillo; Derek Fine; Yuji Zhang; Laurence Magder; Deepak A Rao; Arnon Arazi; Celine C Berthier; Anne Davidson; Betty Diamond; Nir Hacohen; David Wofsy; William Apruzzese; Soumya Raychaudhuri; Michelle Petri Journal: JCI Insight Date: 2020-06-18
Authors: Louise Watson; Kjell Tullus; Clarissa Pilkington; Christine Chesters; Stephen D Marks; Paul Newland; Caroline A Jones; Michael W Beresford Journal: Pediatr Nephrol Date: 2013-11-16 Impact factor: 3.714